duloxetine / Generic mfg. - LARVOL DELTA

Fever and syndrome of inappropriate antidiuretic hormone secretion in a patient with multiple system atrophy after treatment with duloxetine. (PubMed, Neurol Sci) - "Duloxetine may trigger fever and worsen hyponatremia due to SIADH in patients with MSA, possibly by increasing hypothalamic stress. Duloxetine should be used cautiously in MSA, with close monitoring of temperature and serum sodium, particularly in patients with pre-existing hyponatremia or suspected hypothalamic involvement."

Journal • Cardiovascular • CNS Disorders • Critical care • Heart Failure • Infectious Disease • Movement Disorders • Multiple System Atrophy • Pain • Pneumonia • Respiratory Diseases

Examining individual serotonin and norepinephrine reuptake inhibitors and fall-related hospitalizations in older adults. (PubMed, Ment Health Clin) - "Data were drawn from Merative MarketScan Medicare Supplemental claims (January 1, 2015 to November 30, 2021), including adults 65 years and older prescribed an SNRI (ie, duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran). Venlafaxine appears to have a lower fall risk than duloxetine. Further studies are needed to determine clinical significance and assess fall-related costs to support safer SNRI use in older adults."

Journal • Geriatric Disorders

Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain. (PubMed, Clin Pharmacol Ther) - "The rate of MACE was higher for pregabalin users compared to duloxetine users (unadjusted HR: 1.61 (95% CI: 1.43-1.81), adjusted HR: 1.24 (95% CI: 1.08-1.41)), driven by higher rates of HF and AMI among pregabalin users. These findings present new considerations regarding the comparative cardiovascular safety of therapeutic options for chronic musculoskeletal pain."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Musculoskeletal Diseases • Musculoskeletal Pain • Myocardial Infarction • Oncology • Pain

Cost-Effectiveness of Pregabalin, Duloxetine, and Milnacipran vs Amitriptyline for Moderate to Severe Fibromyalgia. (PubMed, JAMA Netw Open) - "Amitriptyline provided greater net benefit than milnacipran and the lower doses of pregabalin and duloxetine. These findings may help inform the selection of value-based treatments for moderate to severe FM."

HEOR • Journal • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

Pregabalin and Duloxetine in Painful Diabetic Neuropathy: Comparative Evidence and the Need to Advance Towards Combination Therapies. (PubMed, Pain Med) - No abstract available

Journal • Diabetic Neuropathy • Pain

Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study. (PubMed, BMC Med) - P3 | "Intravenous high-dose selenium safely failed to reduce grade 1 or more CIPN, whereas it reduced grade 2 or more motor dysfunction during chemotherapy in patients with PSROC, especially those ≥ 60 years. While the primary endpoint was not met, selenium showed the potential of protective effects against motor neuropathy without safety and survival concerns."

Journal • P3 data • Platinum sensitive • Oncology • Ovarian Cancer • Pain • Solid Tumor

Prediction of 12-Week Remission in Patients With Depressive Disorder Using Reasoning-Based Large Language Models: Model Development and Validation Study. (PubMed, JMIR Ment Health) - "We analyzed data from 390 patients in the MAKE Biomarker discovery study who were undergoing first-step antidepressant monotherapy with 12 different medications, including escitalopram, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, milnacipran, mirtazapine, bupropion, vortioxetine, tianeptine, and trazodone, after excluding those with uncommon medications (n=9) or missing biomarker data (n=32). Clinical evaluation by psychiatrists showed favorable mean ratings for correctness (4.3, SD 0.7), consistency (4.2, SD 0.8), specificity (4.2, SD 0.7), helpfulness (4.2, SD 1.0), and human likeness (3.6, SD 1.7) on 5-point scales. These findings demonstrate that reasoning-based LLMs, particularly when enhanced with research-informed prompting, show promise for predicting antidepressant response and could serve as interpretable adjunctive tools in depressive disorder treatment planning, although prospective validation in real-world clinical settings remains..."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

STAMD: Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (clinicaltrials.gov) - P1/2 | N=520 | Recruiting | Sponsor: First Affiliated Hospital of Chongqing Medical University | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Cistanche tubulosa phenylethanol glycoside liposome ameliorates oxaliplatin-induced peripheral neuropathy by promoting RNA N6-methyladenosine modification. (PubMed, Phytomedicine) - "CPhG alleviates oxaliplatin-induced peripheral neuropathy by dual mechanisms: reducing neuroinflammation via IL-6 suppression and promoting neuronal survival and regeneration through AKT activation and m6A-dependent epitranscriptomic regulation. Compared with duloxetine, CPhG demonstrated superior neuroprotective and anti-inflammatory effects, supporting its potential as a novel therapeutic agent for OIPN."

Journal • Immunology • Inflammation • Oncology • Pain • FTO • IL6 • METTL14 • METTL3

Risks of tramadol and gabapentin use for pain. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Pain

Rapid Antidepressant Effects of Low-Dose Intravenous Esketamine in Patients with Chronic Pain (ChiCTR) - P4 | N=450 | Not yet recruiting | Sponsor: Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer

New P4 trial • Pain

Delayed Diagnosis of a Rare Case of Melorheostosis Affecting Both Upper Limbs. (PubMed, Cureus) - "We diagnosed her as a case of melorheostosis involving both upper limbs. She was treated with zoledronic acid, non-steroidal anti-inflammatory drugs (NSAIDs), duloxetine, pregabalin, and ongoing calcium and Vitamin D supplementation. Subsequent follow-up visits at 3, 6, and 12 months showed improvement in pain, with a halt to the progression of swelling."

Journal • Orthopedics • Pain • Rare Diseases

Effects of celecoxib combined with duloxetine on chronic pain, depression, and anxiety in patients with knee osteoarthritis. (PubMed, World J Psychiatry) - "In patients with KOA, celecoxib plus duloxetine effectively mitigates chronic pain and improves anxiety and depressive symptoms without increasing adverse hepatic or renal effects. These findings support its use as a safe and effective treatment option."

Journal • CNS Disorders • Depression • Immunology • Mood Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Psychiatry • Rheumatology

Conservative Treatment in Stress Urinary Incontinence-Narrative Literature Review. (PubMed, Life (Basel)) - "Conservative management, centered on PFMT, should be offered as initial treatment to most women with mild to moderate SUI, with additional modalities being used selectively according to symptom profile, comorbidities and patient preference. A stepwise, individualized approach can control symptoms in many women and may delay or avoid surgical therapy."

Journal • Review • Urinary Incontinence • Urology

Management of neuropathic pain: Don't lose hope! (PubMed, Rev Prat) - "The therapeutic section covers first-line treatments, such as antidepressants (duloxetine, amitriptyline) and antiepileptics (gabapentin, pregabalin), emphasizing dosage and patient management in primary care. This multimodal approach is crucial for effective management, especially in chronic cases, while referral to pain specialists is recommended for complex or refractory cases. By adopting these strategies, GPs can offer significant relief to patients with neuropathic pain, improving their quality of life and reducing the burden on the healthcare system."

Journal • Review • CNS Disorders • Neuralgia • Pain

Review of fibromyalgia treatment guidelines: part 2 - pharmacological treatment. (PubMed, Adv Rheumatol) - No abstract available

Journal • Review • Fibromyalgia • Musculoskeletal Pain • Pain • Rheumatology

A green TLC-densitometric bioanalytical method for concurrent determination of duloxetine and risperidone in human plasma with in-silico DDI evaluation. (PubMed, BMC Chem) - "An internal standard; propranolol (PRP); was used to account for small variations in the samples. Additionally, the method's figures of merits were within the accepted criteria, according to the US-FDA bio-analytical guidelines. Furthermore, drug-drug interactions (DDI) evaluation was conducted using web-based DDI tool to examine the interaction manifestations and to verify safety and therapeutic effectiveness of this combination."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Combination of Duloxetine and Pregabalin to Improve Postoperative Pain (clinicaltrials.gov) - P1 | N=90 | Completed | Sponsor: Cairo University | Not yet recruiting ➔ Completed | Trial completion date: Jun 2023 ➔ Jan 2026 | Trial primary completion date: May 2023 ➔ Dec 2025

Trial completion • Trial completion date • Trial primary completion date • Aesthetic Medicine • Pain

Duloxetine Does Not Reduce Opioid Use Following Total Knee Arthroplasty: A Randomized Controlled Trial (AAOS 2026) - "In this RCT, duloxetine administration in the perioperative period for patients undergoing TKA did not reduce postoperative pain or opioid consumption following surgery."

Clinical • Orthopedics • Pain

MACS-2: Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2025 ➔ Oct 2026 | Trial primary completion date: Dec 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Cough • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

MACS-1: Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Chronic Cough • Cough • Pulmonary Disease • Respiratory Diseases

Not Available (PubMed, Psychiatry Clin Psychopharmacol) - "In 2024, she received four 56 mg doses of Spravato over 2 weeks while maintaining duloxetine, fluvoxamine, and clozapine therapy. No severe adverse events (dissociation, psychosis, or hypertensive crises) were observed. Although limited by an abbreviated treatment regimen and a single-case design, this case suggests that esketamine may be considered in carefully selected TRD patients with structural brain abnormalities and prior ECT poor response, pending validation from larger studies."

Journal • CNS Disorders • Depression • Psychiatry • Suicidal Ideation • Vascular Neurology

Exploring the effects of pharmacological treatments on suicidality in children and adolescents: a structured review of the literature and narrative synthesis. (PubMed, EClinicalMedicine) - "Esketamine (four studies, n = 211) and ketamine (four, n = 6) use in major depressive disorder induced rapid reduction of acute suicidality within 24 h. In the longer term, lithium (three, n = 923) was beneficial in reducing suicidality in youths with bipolar disorder. Sertraline, citalopram, escitalopram, fluoxetine and duloxetine (six, n = 906) yielded inconsistent results. Other agents, including valproate, lamotrigine and antipsychotics such as clozapine and quetiapine exhibited some benefit in reducing suicidality, but findings were limited to small-scale studies...Further high-quality studies investigating suicidal thoughts and behaviours as independent treatment targets are needed to guide clinical decision-making. None."

Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry • Suicidal Ideation

Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy (CIPN)—A randomized, double-blind, placebo-controlled phase II study. (ASCO 2025) - P2/3 | "We were unable to show that any dose of duloxetine was more promising than placebo, possibly due to an unexpectedly high placebo response rate. Low duloxetine/placebo adherence may have compromised efficacy. Placebo-response mitigation methods should be considered in future CIPN clinical trials."

Clinical • P2 data • Colorectal Cancer • Fatigue • Oncology • Pain • Solid Tumor

Severe, Unremitting Piriformis Syndrome Following Yoga and Pilates: A Case Report. (PubMed, Cureus) - "She began to show clinical improvement only after her duloxetine dose was increased back to 60 mg and amitriptyline was added, with full pain recovery occurring three weeks thereafter. The use of psychiatric medication for pain management in patients with PS or other sport-related injuries must be investigated further. This case underlines the importance of addressing holistic factors in managing musculoskeletal pain syndromes."

Journal • CNS Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Psychiatry